The American Journal of the Medical Sciences This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Tumoral calcinosis in an end stage kidney disease patient on peritoneal dialysis
Am J Med Sci. 2023 Oct 14:S0002-9629(23)01394-0. doi: 10.1016/j.amjms.2023.10.005. Online ahead of print.NO ABSTRACTPMID:37844731 | DOI:10.1016/j.amjms.2023.10.005 (Source: The American Journal of the Medical Sciences)
Source: The American Journal of the Medical Sciences - October 16, 2023 Category: General Medicine Authors: Dr Lakshna Sankar Dr Evan Norfolk Dr Kartik Kalra Source Type: research

The Impact of COVID-19 on the Hospitalization and Outcomes of Patients with Alcohol-Related Hepatitis
Am J Med Sci. 2023 Oct 13:S0002-9629(23)01370-8. doi: 10.1016/j.amjms.2023.10.001. Online ahead of print.NO ABSTRACTPMID:37839696 | DOI:10.1016/j.amjms.2023.10.001 (Source: The American Journal of the Medical Sciences)
Source: The American Journal of the Medical Sciences - October 15, 2023 Category: General Medicine Authors: Lavi Oud Source Type: research

The Expanding Role of HLA Gene Tests for Predicting Drug Side Effects
Am J Med Sci. 2023 Oct 12:S0002-9629(23)01375-7. doi: 10.1016/j.amjms.2023.10.004. Online ahead of print.ABSTRACTAdverse drug reactions can be either dose-dependent (Type A) or idiosyncratic (Type B). Type B adverse drug reactions tend to be extremely rare and difficult to predict. They are usually immune-mediated. Examples include severe skin reactions and drug-induced liver injury. For many commonly prescribed drugs (such as antibiotics), the risk of developing an idiosyncratic adverse drug reaction is influenced by variability in the human leukocyte antigen (HLA) genes. Because these HLA-mediated adverse drug reactions ...
Source: The American Journal of the Medical Sciences - October 14, 2023 Category: General Medicine Authors: Natasha Petry Kennedy Forest Russell A Wilke Source Type: research

Polypharmacy in Chronic Kidney Disease: Health Outcomes & amp; Pharmacy-Based Strategies to Mitigate Inappropriate Polypharmacy
Am J Med Sci. 2023 Oct 11:S0002-9629(23)01374-5. doi: 10.1016/j.amjms.2023.10.003. Online ahead of print.ABSTRACTThe rising prevalence of comorbidities in an increasingly aging population has sparked a reciprocal rise in polypharmacy. Patients with chronic kidney disease (CKD) have a greater burden of polypharmacy due to the comorbidities and complications associated with their disease. Polypharmacy in CKD patients has been linked to myriad direct and indirect costs for patients and the society at large. Pharmacists are uniquely positioned within the healthcare team to streamline polypharmacy management in the setting of C...
Source: The American Journal of the Medical Sciences - October 13, 2023 Category: General Medicine Authors: IfeanyiChukwu O Onor Fahamina Ahmed Anthony N Nguyen Michael C Ezebuenyi Collins Uchechukwu Obi Alison K Schafer Amne Borghol Erwin Aguilar John I Okogbaa Efrain Reisin Source Type: research

Periodic generalized edema following COVID-19 infection
Am J Med Sci. 2023 Oct 8:S0002-9629(23)01371-X. doi: 10.1016/j.amjms.2023.10.002. Online ahead of print.ABSTRACTThe unprecedented impact and sequelae of COVID-19 infection are not yet fully understood, and better understanding of the pathophysiology of these infections is needed. Endothelial dysfunction might be common sequelae associated with COVID-19, and increased inflammatory responses, oxidative stress, proinflammatory cytokines, and impaired mitochondrial function also contribute to the pathophysiology of post COVID-19 medical disorders. Systemic capillary leak syndrome following COVID-19 infection, both new onset an...
Source: The American Journal of the Medical Sciences - October 10, 2023 Category: General Medicine Authors: Arunee Motes Kenneth Nugent Source Type: research

Performance of classical serum inflammatory markers in healed and unhealed treated patients with joint and prosthetic joint infections
CONCLUSIONS: Using a cut off value of 25mm/h for ESR, 0.5mg/L for CRP, and 700 ng/ml for D-dimer, it might be possible to discriminate healed from unhealed patients (PPV and NPV: ESR 65.5% and 68.8%, CRP 71.9% and 79.3%, D-dimer 76.9% and 81.8%). The combined use of these three inflammatory markers might be useful in the management of joint infections.PMID:37797825 | DOI:10.1016/j.amjms.2023.09.026 (Source: The American Journal of the Medical Sciences)
Source: The American Journal of the Medical Sciences - October 5, 2023 Category: General Medicine Authors: Enrico Maria Zardi Edoardo Giovannetti de Sanctis Francesco Franceschi Source Type: research